CVClaire Vigne

Claire Vigne

*This is an algorithmically generated author record based on publicly available information.

Claire Vigne has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Fernando Noriega

    Research & Development, Sanofi Pasteur, Swiftwater, PA, USA

    2 shared publications
  • Abiel Homero Mascareñas De Los Santos

    1 shared publication
  • Alexandra Rousseau

    Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB), Saint Antoine Hospital, Assistance Publique-Hopitaux de Paris, Paris, France

    1 shared publication
  • Aline Richetin

    Research & Development, Sanofi Pasteur, Marcy l'Etoile, France

    1 shared publication
  • Amel Touati

    APHP, Hôpital Saint Antoine, Unité de Recherche Clinique (URCEST), Centre de Ressources Biologiques (CRB), Paris, France

    1 shared publication
  • Bertrand Dussol

    CIC 14-09, INSERM - Aix Marseille Université – Hôpitaux Universitaires de Marseille, Marseille, France

    1 shared publication

Latest Publications

  • Open Access

    Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants

    by Odile Launay, Rachna Gupta, Tifany Machabert, Eleine Konate, Alexandra Rousseau, Claire Vigne, Francois Beckers, Louis Devlin, Elisabeth Botelho-Nevers, Marine Cachanado, et al.

    Background We previously reported the safety and immunogenicity data from a randomized trial comparing the booster responses of vaccinees who received monovalent (MV) recombinant protein Beta-variant (MVB.1.351) and MV ancestral protein (MVD614) vaccines with AS03 adjuvant (Sanofi/GSK) to booster response of vaccinees who received mRNA MV ancestral strain BNT162b2 vaccine (Pfizer-BioNTech). Methods First booster of the vaccines was administered in adult participants previously primed with 2 doses of MV ancestral strain BNT162b2. A subset of these participants with available blood samples collected at Day 0 (D0), at 28 days (D28), and 3 months (M3) post-booster were contacted for additional testing (195/208 participants). The persistence of cross-neutralizing antibodies, including against Omicron BA.1 and BA.4/5, up to 3 months after boosting was evaluated using a validated pseudovirus neutralization assay. Results Across the whole population, MVB.1.351 vaccine induces highest NAbs titers against Omicron BA.1 and BA.4/5 variants at D28 and M3 post-booster. In participants with SARS-CoV-2 infection between D28 and M3, both MVB.1.351 and BNT162b2 vaccine groups show an increase in GMTs against Omicron BA.1 and Omicron BA.4/5 following infection. Among uninfected participants, the ratio of M3 to D28 GMTs was higher for the MVB.1.351 group than the BNT162b2 group against Omicron BA.1 (0.64 [0.53;0.77] versus 0.43 [0.35;0.53]), Omicron BA.4/5 (0.61 [0.50; 0.75] versus 0.44 [0.34; 0.56]), and D614 (0.68 [0.58,0.81] versus 0.46 [0.39,0.55]). Conclusions The MVB.1.351 vaccine induces higher and durable cross-neutralizing antibodies against Omicron subvariants up to 3 months after boosting compared to an MV ancestral and mRNA BNT162b2 booster vaccine.


  • Open Access

    Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico

    by Jose Luis Arredondo, Sandra Maria Villagomez Martinez, Maria Concepcion Morales, Stephanie Meyer, Myew-Ling Toh, Celine Zocchetti, Claire Vigne, Cesar Mascareñas


  • Open Access

    Statistical modeling alongside observational data predicts long-term immunogenicity of one dose and two doses of pediatric hepatitis A vaccine in the Mendoza province of Argentina

    by C. Espul, H. Cuello, I. Lo Castro, C. Bravo, Y. Thollot, J. Voznica, C. Vigne, L. Coudeville


  • Open Access

    Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination

    by Claire Vigne, Martin Dupuy, Aline Richetin, Bruno Guy, Nicholas Jackson, Matthew Bonaparte, Branda Hu, Melanie Saville, Danaya Chansinghakul, Fernando Noriega, et al.

    Two large pivotal phase III studies demonstrated the efficacy of the tetravalent dengue vaccine (CYD-TDV; Dengvaxia®, Sanofi Pasteur) against all dengue serotypes. Here we present an unprecedented integrated summary of the immunogenicity of CYD-TDV to identify the parameters driving the neutralizing humoral immune response and evolution over time. We summarized the immunogenicity profiles of a 3-dose schedule of CYD-TDV administered 6 months apart across 10 phase II and 6 phase III trials undertaken in dengue endemic and non-endemic countries. Dengue neutralizing antibody titers in sera were determined at centralized laboratories using the 50% plaque reduction neutralization test (PRNT50) at baseline, 28 d after the third dose, and annually thereafter for up to 4 y after the third dose in some studies. CYD-TDV elicits neutralizing antibody responses against all 4 dengue serotypes; geometric mean titers (GMTs) increased from baseline to post-dose 3. GMTs were influenced by several parameters including age, baseline dengue seropositivity and region. In the 2 pivotal studies, GMTs decreased initially during the first 2 y post-dose 3 but appear to stabilize or slightly increase again in the third year. GMTs persisted 1.2–3.2-fold higher than baseline levels for up to 4 y post-dose 3 in other studies undertaken in dengue endemic countries. Our integrated analysis captures the fullness of the CYD-TDV immunogenicity profile across studies, age groups and regions; by presenting the available data in this way general trends and substantial outliers within each grouping can be easily identified. CYD-TDV elicits neutralizing antibody responses against all dengue serotypes, with differences by age and endemicity, which persist above baseline levels in endemic countries.


  • Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15–18 Months of Age in Mexico

    by Flor Irene Rodriguez Melo, José Juan Renteria Morales, Abiel Homero Mascareñas De Los Santos, Enrique Rivas, Claire Vigne, Fernando Noriega

    BACKGROUND The live, attenuated, tetravalent dengue vaccine (CYD-TDV) is licensed in a number of dengue endemic countries for individuals ≥9 years old. Before integration of any vaccine into childhood vaccination schedules, a lack of immune interference and acceptable safety when co-administered with other recommended vaccines should be demonstrated. METHODS This randomized, multi-center, Phase III trial was conducted in Mexico. Healthy toddlers (n=732) received a booster dose of a licensed pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, and Haemophilus influenzae type b [DTaP-IPV//Hib]) either concomitantly or sequentially with the second dose of CYD-TDV administered as a 3-dose schedule. Antibody titers against diphtheria toxoid, tetanus toxoid and pertussis antigens were measured by enzyme-linked immunosorbent assay. Antibodies against poliovirus and dengue serotypes were measured using a plaque reduction neutralization test. Non-inferiority was demonstrated for each of the DTaP-IPV//Hib antigens if the lower limit of the 2-sided 95% confidence interval of the difference in seroconversion rates between the 2 groups (CYD-TDV - placebo) was >-10%. Safety of both vaccines was assessed. RESULTS Non-inferiority in immune response was demonstrated for all DTaP-IPV//Hib antigens. After 3 doses of CYD-TDV no difference was observed in the immune response for CYD-TDV between groups. There were no safety concerns during the study. CONCLUSION Co-administration of the DTaP-IPV//Hib booster vaccine with CYD-TDV has no observed impact on the immunogenicity or safety profile of the DTaP-IPV//Hib booster vaccine. No difference was observed on the CYD-TDV profile when administered concomitantly or sequentially with the DTaP-IPV//Hib booster vaccine.